Author:
Delyon Julie,Michielin Olivier
Reference10 articles.
1. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC);Menzies;Nat Med,2021
2. Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma;Patel;N Engl J Med,2023
3. Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials;Fujiwara;Lancet Oncol,2023
4. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis;Fenioux;Nat Med,2023
5. Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines;Kang;Trends Immunol,2021